http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20020050253-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate | 2000-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20020050253-A |
| titleOfInvention | Antidiabetic formulation and method |
| abstract | Hypoglycemia and (at least approximately substantially the same effect in the treatment of diabetes mellitus in patients who do not have experience compared to antidiabetic agents, including metformin, used in dosages prescribed in approved medical practice for primary treatment of diabetes) Or) metformin (generally used in reduced amounts (less than 800 mg per day) compared to those used in approved medical practice), and one or more sulfonylureas, eg, glyburide, which provides a reduction in side effects such as gastrointestinal side effects. Low dose antidiabetic pharmaceutical formulations are provided that are particularly suitable for the treatment of type 2 diabetes in a patient who has no experience in administering a combination of antidiabetic agents. Diabetes in human patients who are inexperienced in the treatment of diabetes using the above formulations and also using the above formulations to achieve insulin resistance and / or postprandial blood glucose deviation and / or decrease in hemoglobin A1c and / or postprandial insulin increase Treatment is also provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101336499-B1 |
| priorityDate | 1999-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.